Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
REGN•Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to add four long-acting immunology antibodies to their partnership. The companies will split costs and profits equally and have settled earlier litigation over the collaboration.
1. Expanded partnership
The four antibodies target the same type 2 inflammation pathways as Dupixent, which more than 1.5 million patients use across nine indications. Regeneron will lead research and development, while Sanofi will lead global sales; the existing Dupixent profit-sharing terms will not change.
2. Additional option
Regeneron may also join Sanofi’s experimental drug lunsekimig after its late-stage trials for chronic obstructive pulmonary disease are finished.
